Forbion Capital Partners

forbion.com

VCMatch tracks Forbion Capital Partners as an investor focused on Biotech, Pharma, and Foodtech companies, Pre-Seed and Seed rounds, Europe, Benelux, and Netherlands markets, and $183m to $890m check sizes. Upload your deck to compare your startup against the full private matching profile.

Check Size

$183m to $890m

Stages

Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage

Focus Areas

Biotech, Pharma, Foodtech

Geography

Europe, Benelux, and Netherlands

Investment Thesis

Forbion focuses on investing in life sciences and biotech innovations that generate measurable human and planetary health impact while delivering financial returns. They deploy multiple fund strategies across all stages of (bio-)pharmaceutical drug development and extend their biotech expertise into a BioEconomy strategy to back sustainable solutions in food, agriculture, materials and environmental technologies. The firm emphasizes building companies as well as selecting and supporting early-stage and growth companies to reach value inflection points, and explicitly integrates ESG principles by prioritising patient impact, societal benefits and sustainability.

Is Forbion Capital Partners right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Forbion Capital Partners is most relevant for founders raising Pre-Seed, Seed, and Series A rounds in Biotech, Pharma, Foodtech, and Agtech, especially across Europe, Benelux, and Netherlands, with public check-size signals around $183m to $890m.

Focus statement

Forbion invests in innovative biotech companies across all stages with two complementary strategies: Human Health (advancing therapies that address unmet medical needs) and Planetary Health (via a BioEconomy fund that backs biotech-enabled solutions for sustainable food, agriculture, materials and environmental technologies).

Value Add

Multi-strategy, multi-stage platform: they 'manage just over €5 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development.'
Dual mandate for human and planetary health: 'At Forbion, we invest in life sciences innovations that improve both human and planetary health.'
Dedicated BioEconomy fund targeting sustainability: they 'leverage our biotech expertise beyond human health to address planetary health challenges through our BioEconomy fund strategy.'
Company-building capability: 'Companies that we build make up about one third of the Ventures portfolio.'
Regional strength with global reach: 'a leading global venture capital firm with deep expertise in Europe' with offices in the Netherlands, Germany and the US and a joint venture with BGV for seed/early stage in Benelux and Germany.
ESG / impact integration: 'Since impacting the future is our ethos, we integrate ESG principles into our human and planetary health investments by focusing on patient impact, societal benefits, and sustainability.'